Anixa Biosciences, Inc. (ANIX) is a clinical-stage oncology company, and analyst coverage is thin — typical for a micro-cap biotech. The $10 central target is the mean of three attributable price targets: H.C. Wainwright's Yi Chen reiterated a Buy with a $6 target (recently lowered from $7); D. Boral Capital's Jason Kolbert initiated coverage with a $10 target; and Maxim Group's Jason McCarthy maintained a Buy with a $14 target. That gives a $6–$14 range and an average of $10.
Some aggregators report a slightly different average (near $9.67) or a fourth, lower target, illustrating how much these figures shift with a small analyst base. The views are all nominally bullish, but the threefold spread between the low and high targets signals genuine disagreement about how to value a company with no marketed product.
At roughly $3.28, ANIX carries a market capitalization near $114 million and sits in the lower portion of its 52-week range of about $2.32 to $5.46. Moving to $10 would require a gain of approximately 205% — a very large move for any equity, and especially demanding for a pre-revenue developer.
That path would almost certainly be driven by clinical data rather than fundamentals such as earnings or sales, because Anixa currently records essentially no revenue. Its lead program is a chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer, where a first patient has been dosed in a Phase 1 trial, alongside a breast cancer vaccine program. Positive early safety and efficacy signals have historically been the catalysts that re-rate such names sharply.
The 52-week low near $2.32 is a key support zone to watch, while the prior high near $5.46 is the most relevant resistance level on the way toward any higher target. A sustained move above the mid-$3 area would first need to clear that prior high, after which the round-number levels of $6 and $10 become psychological milestones. For a lightly traded name, these levels should be treated as zones rather than precise points.
Analyst price targets typically reflect a roughly 12-month horizon, though for a clinical-stage company the realistic path to value may extend well beyond that. Key items to monitor include quarterly results (the company reported earnings in early September 2026, with the next report expected around early January 2027), updates on trial enrollment and data readouts, cash position and any financing announcements, and analyst rating or target revisions. Regulatory feedback on trial design and any partnership or licensing news would also be material.
For traders tracking a volatile micro-cap like ANIX, Tickeron's AI Daily Buy/Sell Signals offer an additional layer of monitoring. The system uses artificial intelligence to continuously scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. It is designed to help traders discover opportunities, keep an eye on existing positions, and spot changing trends more efficiently than manual review allows. Consider pairing fundamental research with these signals as part of a broader, disciplined approach to decision-making.
The question of whether ANIX can reach $10 ultimately hinges on clinical execution rather than near-term financials. The $10 target — the mean of three analyst targets ranging from $6 to $14 — implies a very large, roughly 205% move from the current price. Support comes from an oncology pipeline with meaningful catalysts and a wide analyst spread that reflects both high potential and high uncertainty. The principal obstacles are the inherent failure risk of early-stage drug development, recurring losses, and possible dilution. Investors should watch trial data, the cash position, and analyst revisions, while recognizing that no target represents a guarantee of future performance.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ANIX has been loosely correlated with PRME. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIX jumps, then PRME could also see price increases.
| Ticker / NAME | Correlation To ANIX | 1D Price Change % | ||
|---|---|---|---|---|
| ANIX | 100% | -3.16% | ||
| PRME - ANIX | 45% Loosely correlated | -9.30% | ||
| TNYA - ANIX | 43% Loosely correlated | -5.94% | ||
| RXRX - ANIX | 42% Loosely correlated | -6.70% | ||
| RCKT - ANIX | 41% Loosely correlated | -3.16% | ||
| CRSP - ANIX | 41% Loosely correlated | -9.77% | ||
More | ||||